Cystic fibrosis pulmonary exacerbations attributable to respiratory syncytial virus and influenza: A population-based study

Clinical Infectious Diseases

Volumn 64, Issue 12, 2017, Pages 1760-1767

  Somayaji, Ranjani ^a,b   Goss, Christopher H ^b   Khan, Umer ^c   Neradilek, Moni ^d   Neuzil, Kathleen M ^e   Ortiz, Justin R ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d Mountain Whisper Light Statistics   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

Author keywords

cystic fibrosis; influenza virus; pulmonary exacerbations; respiratory syncytial virus; surveillance

Indexed keywords

ANTIBIOTIC AGENT;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFECTION RISK; INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VIRUS; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY VIRUS; RISK FACTOR; SCHOOL CHILD; SEASONAL INFLUENZA; SENSITIVITY ANALYSIS; SOCIOECONOMICS; VIRUS DETECTION; YOUNG ADULT; AGE DISTRIBUTION; COMPLICATION; EPIDEMIOLOGICAL MONITORING; HOSPITALIZATION; INCIDENCE; INFLUENZA; LUNG; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; REGISTER; VIROLOGY;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYSTIC FIBROSIS; DISEASE PROGRESSION; EPIDEMIOLOGICAL MONITORING; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; INFLUENZA, HUMAN; LUNG; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGISTRIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTORS; YOUNG ADULT;

EID: 85020466625     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix203     Document Type: Article

References (44)

1. Knapp EA, Fink AK, Goss CH, et al. The cystic fibrosis foundation patient registry. Design and methods of a national observational disease registry. Ann Am Thorac Soc 2016; 13: 1173-9
2. Cystic Fibrosis Foundation. Patient registry annual data report 2012. Bethesda, MD: Cystic Fibrosis Foundation 2012
3. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax 2007; 62: 360-7
4. Stenbit AE, Flume PA. Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med 2011; 17: 442-7
5. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001; 153: 345-52
6. Folescu TW, da Costa CH, Cohen RW, da Conceicao Neto OC, Albano RM, Marques EA. Burkholderia cepacia complex: clinical course in cystic fibrosis patients. BMC Pulm Med 2015; 15: 158
7. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100
8. Ramsey BW, Gore EJ, Smith AL, Cooney MK, Redding GJ, Foy H. The effect of respiratory viral infections on patients with cystic fibrosis. Am J Dis Child 1989; 143: 662-8
9. Ortiz JR, Neuzil KM, Victor JC, Wald A, Aitken ML, Goss CH. Influenzaassociated cystic fibrosis pulmonary exacerbations. Chest 2010; 137: 852-60
10. Armstrong D, Grimwood K, Carlin JB, et al. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol 1998; 26: 371-9
11. Wang EE, Prober CG, Manson B, Corey M, Levison H. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med 1984; 311: 1653-8
12. Wat D, Gelder C, Hibbitts S, et al. The role of respiratory viruses in cystic fibrosis. J Cyst Fibros 2008; 7: 320-8
13. Hament JM, Kimpen JL, Fleer A, Wolfs TF. Respiratory viral infection predisposing for bacterial disease: a concise review. FEMS Immunol Med Microbiol 1999; 26: 189-95
14. Van Ewijk BE, Wolfs TF, Aerts PC, et al. RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr Res 2007; 61: 398-403
15. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 1988; 113: 826-30
16. Pribble CG, Black PG, Bosso JA, Turner RB. Clinical manifestations of exacerbations of cystic fibrosis associated with nonbacterial infections. J Pediatr 1990; 117: 200-4
17. Burns JL, Emerson J, Kuypers J, et al. Respiratory viruses in children with cystic fibrosis: viral detection and clinical findings. Influenza Other Respir Viruses 2012; 6: 218-23
18. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375: 1545-55
19. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352: 1749-59
20. Ortiz JR, Neuzil KM, Victor JC, Wald A, Aitken ML, Goss CH. Influenzaassociated cystic fibrosis pulmonary exacerbations. Chest 2010; 137: 852-60
21. Centers for Disease Control and Prevention. Overview of influenza surveillance in the United States. Atlanta, GA: CDC 2006
22. Centers for Disease Control and Prevention. The National Respiratory and Enteric Virus Surveillance System (NREVSS). Atlanta, GA: CDC. Available at: https://www.cdc.gov/surveillance/nrevss/rsv/natl-trend.html. Accessed on 1 August 2016
23. Centers for Disease Control and Prevention. Past weekly surveillance reports. Available at: https://www.cdc.gov/flu/weekly/pastreports.htm. Accessed on 1 August 2016
24. Centers for Disease Control and Prevention. Fluview - A weekly influenza surveillance report prepared by the Influenza Division. Atlanta, GA: CDC 2016
25. Ortiz JR, Zhou H, Shay DK, Neuzil KM, Fowlkes AL, Goss CH. Monitoring influenza activity in the United States: a comparison of traditional surveillance systems with Google flu trends. PLoS One 2011; 6: e18687
26. Ortiz JR, Neuzil KM, Rue TC, et al. Population-based incidence estimates of influenza-associated respiratory failure hospitalizations, 2003 to 2009. Am J Respir Crit Care Med 2013; 188: 710-5
27. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG Jr. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993; 15: 75-88
28. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159: 179-87
29. Chandra P, Wolfenden LL, Ziegler TR, et al. Treatment of vitamin D deficiency with UV light in patients with malabsorption syndromes: a case series. Photodermatol Photoimmunol Photomed 2007; 23: 179-85
30. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2013
31. Freymuth F, Vabret A, Galateau-Salle F, et al. Detection of respiratory syncytial virus, parainfluenzavirus 3, adenovirus and rhinovirus sequences in respiratory tract of infants by polymerase chain reaction and hybridization. Clin Diagn Virol 1997; 8: 31-40
32. Greenberg SB, Allen M, Wilson J, Atmar RL. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 167-73
33. Smith CB, Kanner RE, Golden CA, Klauber MR, Renzetti AD Jr. Effect of viral infections on pulmonary function in patients with chronic obstructive pulmonary diseases. J Infect Dis 1980; 141: 271-80
34. Wiselka MJ, Kent J, Cookson JB, Nicholson KG. Impact of respiratory virus infection in patients with chronic chest disease. Epidemiol Infect 1993; 111: 337-46
35. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289: 179-86
36. Rello J, Pop-Vicas A. Clinical review: primary influenza viral pneumonia. Crit Care 2009; 13: 235
37. Ortiz JR, Neuzil KM, Victor JC, Aitken ML, Goss CH. Predictors of influenza vaccination in the cystic fibrosis foundation patient registry, 2006 through 2007. Chest 2010; 138: 1448-55
38. Wat D, Gelder C, Hibbitts S, et al. Is there a role for influenza vaccination in cystic fibrosis? J Cyst Fibros 2008; 7: 85-8
39. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis 2016; 16: 942-51
40. Fiore A, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2011; 60: 1-24
41. Robinson K, Odelola OA, Saldanha IJ, McKoy NA. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev 2013; 6: CD007743
42. Piedra PA, Cron SG, Jewell A, et al. Purified Fusion Protein Vaccine Study Group. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine 2003; 21: 2448-60
43. Piedra PA, Grace S, Jewell A, et al. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J 1996; 15: 23-31
44. Thompson WW, Weintraub E, Dhankhar P, et al. Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respir Viruses 2009; 3: 37-49